Test ID HIBS Haemophilus influenzae Type B Antibody, IgG, Serum
Reporting Name
Haemophilus influenzae B Ab, IgG, SUseful For
Assessing a patient's immunological (IgG) response to Haemophilus influenzae type B (HIB) vaccine
Assessing immunity against HIB
Aiding in the evaluation of immunodeficiency when the patient is tested pre- and postvaccination
Specimen Type
SerumSpecimen Required
Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Specimen Volume: 0.5 mL
Specimen Minimum Volume
0.2 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 7 days | |
Frozen | 7 days |
Reference Values
≥0.15 mg/L
Reference values apply to all ages.
Day(s) and Time(s) Performed
Monday, Wednesday, Friday; 8 a.m.
Test Classification
This test has been cleared, approved or is exempt by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.CPT Code Information
86684
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
HIBS | Haemophilus influenzae B Ab, IgG, S | 11257-3 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
83261 | Haemophilus influenzae B Ab, IgG, S | 11257-3 |
Clinical Information
Haemophilus influenzae type B (HIB) is an encapsulated gram-negative cocco-bacillary bacterium that can cause devastating disease in young children including meningitis, bacteremia, cellulitis, epiglottitis, pneumonia, and septic arthritis.
One of the great advances in modern medicine has been the development of an effective vaccine against HIB. A patient's immunological response to HIB vaccine can be determined by measuring anti-HIB IgG antibody using this enzyme immunoassay (EIA) technique.
Interpretation
An anti-Haemophilus influenzae type B (HIB) IgG antibody concentration of 0.15 mg/L is generally accepted as the minimum level for protection at a given time; however, it does not confer long-term protection. A study from Finland suggested that the optimum protective level is 1.0 mg/L postimmunization.(1) Furthermore, studies have shown that the response to HIB vaccine is age-related.
Clinical Reference
1. Peltola H, Kayhty H, Virtanen M, et al: Prevention of Haemophilus influenzae type B bacteremic infections with the capsular polysaccharide vaccine. N Engl J Med. 1984;310(24):1561-1566
2. Berger M: Immunoglobulin G subclass determination in diagnosis and management of antibody deficiency syndromes. J Pediatr. 1987;110(2):325-328
3. Murphy TF: Haemophilus species, including H influenzae and H ducreyi (Chancroid). In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 9th ed. Elsevier; 2020:2743-2752
Analytic Time
Same day/1 dayMethod Name
Enzyme Immunoassay (EIA)
Forms
If not ordering electronically, complete, print, and send a Microbiology Test Request (T244) with the specimen.